Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chinese scientists to pioneer first human CRISPR trial.

× No keyword cloud information.

47 in total

Review 1. Recent advances in liposome formulations for breast cancer therapeutics.

Authors: Biyao Yang; Bo-Ping Song; Shaina Shankar; Anna Guller; Wei Deng
Journal: Cell Mol Life Sci Date: 2021-05-11 Impact factor: 9.261

2. Orphan drug development in China - Turning challenges into opportunities.

Authors: Xiaowei Jin; Li Chen
Journal: Intractable Rare Dis Res Date: 2016-11

Review 3. What rheumatologists need to know about CRISPR/Cas9.

Authors: Gary J Gibson; Maozhou Yang
Journal: Nat Rev Rheumatol Date: 2017-02-09 Impact factor: 20.543

Review 4. CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.

Authors: Vera Paschon; Felipe Fernandes Correia; Beatriz Cintra Morena; Victor Allisson da Silva; Gustavo Bispo Dos Santos; Maria Cristina Carlan da Silva; Alexandre Fogaça Cristante; Stephanie Michelle Willerth; Florence Evelyne Perrin; Alexandre Hiroaki Kihara
Journal: Mol Neurobiol Date: 2020-01-11 Impact factor: 5.590

Review 5. Genome and Epigenome Editing in Mechanistic Studies of Human Aging and Aging-Related Disease.

Authors: Cia-Hin Lau; Yousin Suh
Journal: Gerontology Date: 2016-12-15 Impact factor: 5.140

Review 6. Cornerstones of CRISPR-Cas in drug discovery and therapy.

Authors: Christof Fellmann; Benjamin G Gowen; Pei-Chun Lin; Jennifer A Doudna; Jacob E Corn
Journal: Nat Rev Drug Discov Date: 2016-12-23 Impact factor: 84.694

Review 7. From phenologs to silent suppressors: Identifying potential therapeutic targets for human disease.

Authors: Andy Golden
Journal: Mol Reprod Dev Date: 2017-10-03 Impact factor: 2.609

8. [Development and applications of CRISPR/Cas9 library screening technology in cancer research].

Authors: Ting Lei; Bin Xiao; Yongyin He; Jing Qu; Zhaohui Sun; Linhai Li
Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2019-11-30

9. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.

Authors: Sunil S Raikar; Lauren C Fleischer; Robert Moot; Andrew Fedanov; Na Yoon Paik; Kristopher A Knight; Christopher B Doering; H Trent Spencer
Journal: Oncoimmunology Date: 2017-12-26 Impact factor: 8.110

Review 10. CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment.

Authors: Itishree Kaushik; Sharavan Ramachandran; Sanjay K Srivastava
Journal: Semin Cell Dev Biol Date: 2019-05-04 Impact factor: 7.727